Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2022 Jan 13

PMID 35023972

Authors

Giulia Marvaso

Stefania Volpe

Matteo Pepa

Mattia Zaffaroni

Giulia Corrao

Matteo Augugliaro

Franco Nole

Ottavio de Cobelli

Barbara Alicja Jereczek-Fossa

Affiliations

Soon will be listed here.

Abstract

After primary treatment for prostate cancer with either radical prostatectomy or radiotherapy, a significant proportion of patients are at risk of developing metastases. In recent years, a deeper understanding of the underlying biology together with improved imaging techniques and the advent of new therapeutic options including metastases-directed therapies and new drugs have revolutionized the management of low-burden metastatic disease, also known as oligometastatic state. The purpose of this narrative review is to report the recent developments in the management of hormone-sensitive oligometastatic prostate cancer patients.

Citing Articles

A Bibliometric Analysis of the Oligometastatic State over the Last Two Decades: A Shifting Paradigm for Oncology? An AIRO Oligometastatic Study Group.

Marvaso G, Mastroleo F, Corrao G, Zaffaroni M, Vincini M, Borghetti P Cancers (Basel). 2023; 15(15).

PMID: 37568718 PMC: 10417037. DOI: 10.3390/cancers15153902.

References

Lussier Y, Khodarev N, Regan K, Corbin K, Li H, Ganai S . Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141. PMC: 3518475. DOI: 10.1371/journal.pone.0050141. View

Sonpavde G . The biology of prostate cancer metastases: does oligo differ from polymetastatic?. Curr Opin Urol. 2017; 27(6):542-546. DOI: 10.1097/MOU.0000000000000434. View

Ghosh R, Pandey T, Dey P . Liquid biopsy: A new avenue in pathology. Cytopathology. 2018; 30(2):138-143. DOI: 10.1111/cyt.12661. View

Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J . Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. World J Urol. 2018; 37(12):2557-2564. DOI: 10.1007/s00345-018-2609-8. View

Hovels A, Heesakkers R, Adang E, Jager G, Strum S, Hoogeveen Y . The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008; 63(4):387-95. DOI: 10.1016/j.crad.2007.05.022. View

Dhondt B, Rousseau Q, de Wever O, Hendrix A . Function of extracellular vesicle-associated miRNAs in metastasis. Cell Tissue Res. 2016; 365(3):621-41. DOI: 10.1007/s00441-016-2430-x. View

Lecouvet F, Oprea-Lager D, Liu Y, Ost P, Bidaut L, Collette L . Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncol. 2018; 19(10):e534-e545. DOI: 10.1016/S1470-2045(18)30571-0. View

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

Barata P, Sartor A . Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or…. Cancer. 2019; 125(11):1777-1788. DOI: 10.1002/cncr.32039. View

10.

Kucharczyk M, Gravis G, Niazi T . The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer. Eur Urol Focus. 2018; 5(2):117-118. DOI: 10.1016/j.euf.2018.11.011. View

11.

Joice G, Rowe S, Pienta K, Gorin M . Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology. Curr Opin Urol. 2017; 27(6):533-541. DOI: 10.1097/MOU.0000000000000449. View

12.

Sumiyoshi T, Chi K, Wyatt A . Clinical implications of genomic alterations in metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021; 24(2):310-322. DOI: 10.1038/s41391-020-00308-x. View

13.

Salvi S, Gurioli G, De Giorgi U, Conteduca V, Tedaldi G, Calistri D . Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther. 2016; 9:6549-6559. PMC: 5087772. DOI: 10.2147/OTT.S100901. View

14.

Perez-Lopez R, Tunariu N, Padhani A, Oyen W, Fanti S, Vargas H . Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology. 2019; 292(2):273-286. DOI: 10.1148/radiol.2019181931. View

15.

Kyriakopoulos C, Chen Y, Carducci M, Liu G, Jarrard D, Hahn N . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018; 36(11):1080-1087. PMC: 5891129. DOI: 10.1200/JCO.2017.75.3657. View

16.

Davis I, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S . Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019; 381(2):121-131. DOI: 10.1056/NEJMoa1903835. View

17.

Cheng H, Plets M, Li H, Higano C, Tangen C, Agarwal N . Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate. 2017; 78(2):121-127. PMC: 5728359. DOI: 10.1002/pros.23452. View

18.

Padhani A, Lecouvet F, Tunariu N, Koh D, De Keyzer F, Collins D . METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur Urol. 2016; 71(1):81-92. PMC: 5176005. DOI: 10.1016/j.eururo.2016.05.033. View

19.

Mulrane L, McGee S, Gallagher W, OConnor D . miRNA dysregulation in breast cancer. Cancer Res. 2013; 73(22):6554-62. DOI: 10.1158/0008-5472.CAN-13-1841. View

20.

Shen G, Deng H, Hu S, Jia Z . Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014; 43(11):1503-13. DOI: 10.1007/s00256-014-1903-9. View